In Spain, diabetes affects 15% of the adult population, with an annual cost exceeding €15.5 billion. Digital therapeutics (DTx), such as BlueStar and Insulia, offer innovative solutions to improve glycemic control, treatment adherence, and patient education. BlueStar can reduce HbA1c by up to 1.35% and save €500 per patient annually, while Insulia has shown reductions in hypoglycemia and better insulin adjustment.
Over one million patients with poorly controlled type 2 diabetes could benefit, potentially saving €500 million per year. Additionally, DTx contribute to environmental sustainability by reducing medical visits and CO₂ emissions.
The document suggests to develop a national pilot program to evaluate their integration into Spanish National Health System.
